Net interest margin of 13.68% Received SBA approval to complete second SBIC license application Various portfolio companies achieved key milestones during and after the [...]
WINSTON-SALEM, N.C.(BUSINESS WIRE) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics?, today reported its financial results for the third quarter ended September 30, 2009. [...]
Conference call scheduled today at 1:30 p.m. PT; Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO(BUSINESS WIRE) Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development [...]
Company generates 7 percent organic revenue growth and $112 million of free cash flow BILLERICA, Mass.(BUSINESS WIRE) Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for [...]
REDWOOD CITY, Calif., Nov. 5, 2009 (GLOBE NEWSWIRE) Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2009.The net loss for the third quarter of 2009 was $6.2 million compared to $4.6 million for the third quarter of 2008.Research and development expenses were $4.0 million for the third [...]
Nov 05, 2009 (Datamonitor via COMTEX) Transcept Pharmaceuticals, a specialty pharmaceutical company, has received a notice of allowance from the US Patent and Trademark Office for claims under US patent application, which covers the use of Intermezzo, the company’s lead product candidate. Once issued, this patent will expire in February 2025.Under the terms of the [...]
Nov 05, 2009 (Datamonitor via COMTEX) GlaxoSmithKline, a UK-based pharmaceutical group, and Pfizer, a US-based pharmaceutical group, have launched ViiV Healthcare, a new specialist HIV company.ViiV Healthcare has 10 medicines currently available including therapies such as Epzicom/Kivexa and Selzentry/Celsentri. The company also has a pipeline of seven targeted medicines, including five compounds in Phase II [...]
MONTREAL, CANADA (MARKET WIRE) 11/05/09 Theratechnologies (TSX: TH) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration ("FDA") will review Theratechnologies’ NDA for tesamorelin in the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The role of the Advisory Committee, which is [...]
CARLSBAD, Calif., Nov. 5 /PRNewswire-FirstCall/ Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the third quarter ended September 30, 2009. For the quarter, Isis reported a net loss of $3.4 million and a net operating loss of $6.9 million. In addition, for the first nine months of 2009, Isis reported [...]
Dublin – Research and Markets has announced the addition of the "Genetic Engineering – Global Outlook" report to their offering.The global outlook series on Genetic Engineering provides a collection of market briefs and concise summaries of research findings. The report offers a bird’s eye view of the industry, highlights latest developments, and discusses demand drivers, [...]
